Harmony Biosciences Holdings, Inc.
NASDAQ:HRMYBiotechnology
-$0.61 today
- Market cap
- $1.94B
- Beta
- 0.97
- P/E (TTM)
- 13.2
- EPS (TTM)
- $2.52
Volume 0.57M
Average 0.82M
HRMY Net Income
Bottom-line profit after all expenses, interest, and taxes.
Harmony Biosciences Holdings, Inc.NASDAQ: HRMY
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income growth accelerates
Q2 FY2026 net income of $75.43M rose 89.6% year over year, ahead of the +0.2% change in trailing-twelve-month net income. Sequentially, it rose 132.2% from the prior quarter. Over 3 fiscal years it compounded at -4.4% a year.
Context
- Net income amounted to 18.3% of revenue in FY2025, down 2.1 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 9 analysts of $208.75M (+31.6%) for the fiscal year ending Dec 2026, a step up from the +9.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $75.43M+132.2% QoQ
- Last fiscal yearDec 2025
- $158.69M+9.1% YoY
- LTMJun 2026
- $181.27M+0.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +89.6% | +27.6% | -62.0 pp |
| 1 year | +9.1% | +31.6% | +22.5 pp |
| 3-year CAGR | -4.4% | +24.0% | +28.4 pp |
| 5-year CAGR | +13.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- 158.69M USD
- Year-over-year change
- +9.1%
- 4-year CAGR
- +46.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 158.69M | +9.1% |
| FY2024 | 2024-12-31 | 145.49M | +12.9% |
| FY2023 | 2023-12-31 | 128.85M | -29.0% |
| FY2022 | 2022-12-31 | 181.47M | +424.5% |
| FY2021 | 2021-12-31 | 34.6M | — |
Net Income vs competitors
How HRMY compares with its peers on the latest reported figures
- HRMY's LTM Jun 2026 net income of $181.27M is the highest of the 4 companies compared; the peer median is -$178.95M.
- Its year-over-year change of +0.2% is the highest of 3, against a peer median of -1820.8%.
- Net income amounts to 18.9% of revenue for HRMY.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $181.27M | +0.2% | -4.4% | 18.9% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$39.17M | — | — | — |
| LTM Mar 2026 | -$178.95M | -29.9% | — | — | |
| LTM Jun 2026 | -$394.35M | -3611.7% | — | — | |
APMDApnimed, Inc. | — | — | — | — | — |
| Peer median (excluding HRMY) | -$178.95M | -1820.8% | — | — | |
Competitors are the stored peer set for HRMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 305.44M | 437.86M | 582.02M | 714.73M | 868.45M |
| Cost of Revenue | 55.52M | 83.48M | 121.24M | 156.82M | 198.34M |
| Gross Profit | 249.92M | 354.37M | 460.79M | 557.92M | 670.11M |
| Gross Margin | 81.8% | 80.9% | 79.2% | 78.1% | 77.2% |
| Research & Development | 30.37M | 70.89M | 76.06M | 145.83M | 189.59M |
| Selling, General & Admin | 132.03M | 163.3M | 192.69M | 221.27M | 272.05M |
| Operating Expenses | 162.39M | 234.19M | 268.76M | 367.09M | 461.64M |
| Depreciation & Amortization | 18.84M | 23.39M | 24.36M | 24.11M | 25.34M |
| EBITDA | 80.46M | 146.87M | 221.51M | 233.41M | 255.05M |
| EBITDA Margin | 26.3% | 33.5% | 38.1% | 32.7% | 29.4% |
| Operating Income | 87.53M | 120.19M | 192.03M | 190.83M | 208.47M |
| Operating Margin | 28.7% | 27.4% | 33.0% | 26.7% | 24.0% |
| Interest Income | 224K | 3.13M | 14.73M | 18.54M | 21.92M |
| Interest Expense | 24.19M | 18.8M | 23.76M | 17.5M | 14.65M |
| Other Income / Expenses | (50.1M) | (15.5M) | (18.63M) | 978K | 6.6M |
| Income Before Tax | 37.43M | 104.69M | 173.4M | 191.8M | 215.06M |
| Pre-Tax Margin | 12.3% | 23.9% | 29.8% | 26.8% | 24.8% |
| Income Tax Expense | 2.83M | (76.78M) | 44.54M | 46.31M | 56.38M |
| Net Income | 34.6M | 181.47M | 128.85M | 145.49M | 158.69M |
| Net Margin | 11.3% | 41.4% | 22.1% | 20.4% | 18.3% |
| EPS (Basic) | 0.60 | 3.07 | 2.17 | 2.56 | 2.76 |
| EPS (Diluted) | 0.58 | 2.97 | 2.13 | 2.51 | 2.71 |
| Weighted Avg Shares | 57.53M | 59.17M | 59.47M | 56.89M | 57.49M |
| Weighted Avg Shares (Diluted) | 59.21M | 61.1M | 60.37M | 57.87M | 58.54M |
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
Intrinsic Alpha fair value
Locked
Current Price
$33.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.